Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360353 | 1.00 | BACE1 (1.00) | BACE1APP | |
| SCHEMBL1173236 | 0.91 | BACE1 (0.86) | BACE1APP | |
| SCHEMBL10270335 | 0.89 | BACE1 (0.81) | BACE1APP | |
| SCHEMBL15314427 | 0.87 | BACE1 (0.81) | BACE1APP | |
| SCHEMBL362299 | 0.87 | BACE1 (1.00) | BACE1 | |
| SCHEMBL361498 | 0.87 | BACE1 (1.00) | BACE1 | |
| SCHEMBL361585 | 0.87 | BACE1 (1.00) | BACE1 | |
| SCHEMBL361928 | 0.87 | BACE1 (1.00) | BACE1 | |
| SCHEMBL9061657 | 0.87 | BACE1 (0.78) | BACE1APP | |
| SCHEMBL362848 | 0.86 | BACE1 (1.00) | BACE1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207164-B2 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | BACE1 69/4885APP 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.